ES2378314T3 - Predicción de la mortalidad y detección de enfermedades graves. - Google Patents

Predicción de la mortalidad y detección de enfermedades graves. Download PDF

Info

Publication number: ES2378314T3
Authority: ES; Spain
Prior art keywords: subject; level; risk; levels; death
Prior art date: 2006-04-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES10171764T

Other languages

English (en)

Spanish (es)

Inventor

James V. Snider

Sven Jacobson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Critical Care Diagnostics Inc

Original Assignee

Critical Care Diagnostics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-24

Filing date

2007-04-24

Publication date

2012-04-11

2007-04-24 Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc

2012-04-11 Application granted granted Critical

2012-04-11 Publication of ES2378314T3 publication Critical patent/ES2378314T3/es

Status Active legal-status Critical Current

2027-04-24 Anticipated expiration legal-status Critical

Links

201000010099 disease Diseases 0.000 title abstract description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 28
238000001514 detection method Methods 0.000 title abstract description 5
238000000338 in vitro Methods 0.000 claims abstract 3
238000000034 method Methods 0.000 claims description 99
230000034994 death Effects 0.000 claims description 80
231100000517 death Toxicity 0.000 claims description 80
206010013975 Dyspnoeas Diseases 0.000 claims description 37
238000011282 treatment Methods 0.000 claims description 36
208000000059 Dyspnea Diseases 0.000 claims description 32
208000024891 symptom Diseases 0.000 claims description 30
210000002966 serum Anatomy 0.000 claims description 23
238000012360 testing method Methods 0.000 claims description 19
206010008479 Chest Pain Diseases 0.000 claims description 17
101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 claims description 16
201000006370 kidney failure Diseases 0.000 claims description 11
208000001647 Renal Insufficiency Diseases 0.000 claims description 10
208000019693 Lung disease Diseases 0.000 claims description 8
206010033557 Palpitations Diseases 0.000 claims description 7
206010016256 fatigue Diseases 0.000 claims description 7
208000013220 shortness of breath Diseases 0.000 claims description 7
210000002381 plasma Anatomy 0.000 claims description 6
206010008469 Chest discomfort Diseases 0.000 claims description 4
206010015137 Eructation Diseases 0.000 claims description 4
208000008454 Hyperhidrosis Diseases 0.000 claims description 4
206010028813 Nausea Diseases 0.000 claims description 4
206010047700 Vomiting Diseases 0.000 claims description 4
208000027687 belching Diseases 0.000 claims description 4
208000002173 dizziness Diseases 0.000 claims description 4
230000008693 nausea Effects 0.000 claims description 4
230000035900 sweating Effects 0.000 claims description 4
206010042772 syncope Diseases 0.000 claims description 4
210000002700 urine Anatomy 0.000 claims description 4
230000008673 vomiting Effects 0.000 claims description 4
230000007423 decrease Effects 0.000 claims description 3
208000019423 liver disease Diseases 0.000 claims description 3
208000024172 Cardiovascular disease Diseases 0.000 claims description 2
230000003247 decreasing effect Effects 0.000 claims description 2
108010067003 Interleukin-33 Proteins 0.000 abstract description 69
102000017761 Interleukin-33 Human genes 0.000 abstract description 69
239000000090 biomarker Substances 0.000 abstract description 47
238000005259 measurement Methods 0.000 abstract description 30
238000011156 evaluation Methods 0.000 abstract description 16
230000002411 adverse Effects 0.000 abstract description 8
239000012472 biological sample Substances 0.000 abstract description 2
108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 61
102400001263 NT-proBNP Human genes 0.000 description 55
239000000523 sample Substances 0.000 description 47
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 43
101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 38
101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 38
102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 37
238000003745 diagnosis Methods 0.000 description 32
230000008859 change Effects 0.000 description 31
206010019280 Heart failures Diseases 0.000 description 28
229940109239 creatinine Drugs 0.000 description 22
238000004458 analytical method Methods 0.000 description 17
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 14
230000001154 acute effect Effects 0.000 description 14
102100036836 Natriuretic peptides B Human genes 0.000 description 13
101710187802 Natriuretic peptides B Proteins 0.000 description 13
239000003153 chemical reaction reagent Substances 0.000 description 13
238000004393 prognosis Methods 0.000 description 13
238000012546 transfer Methods 0.000 description 13
230000000747 cardiac effect Effects 0.000 description 12
102100038026 DNA fragmentation factor subunit alpha Human genes 0.000 description 11
101710182628 DNA fragmentation factor subunit alpha Proteins 0.000 description 11
238000002965 ELISA Methods 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
239000000243 solution Substances 0.000 description 11
208000010378 Pulmonary Embolism Diseases 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
230000002685 pulmonary effect Effects 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
-1 for example Substances 0.000 description 9
230000024924 glomerular filtration Effects 0.000 description 9
208000010125 myocardial infarction Diseases 0.000 description 9
238000003556 assay Methods 0.000 description 8
208000006673 asthma Diseases 0.000 description 8
230000003907 kidney function Effects 0.000 description 8
102000004903 Troponin Human genes 0.000 description 7
108090001027 Troponin Proteins 0.000 description 7
230000000694 effects Effects 0.000 description 7
230000037081 physical activity Effects 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
238000005070 sampling Methods 0.000 description 7
101800001288 Atrial natriuretic factor Proteins 0.000 description 6
102400001282 Atrial natriuretic peptide Human genes 0.000 description 6
101800001890 Atrial natriuretic peptide Proteins 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 6
238000002405 diagnostic procedure Methods 0.000 description 6
230000003908 liver function Effects 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
238000010837 poor prognosis Methods 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
238000013517 stratification Methods 0.000 description 6
206010007556 Cardiac failure acute Diseases 0.000 description 5
206010020772 Hypertension Diseases 0.000 description 5
206010006451 bronchitis Diseases 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
230000006870 function Effects 0.000 description 5
210000002216 heart Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
230000007170 pathology Effects 0.000 description 5
208000007848 Alcoholism Diseases 0.000 description 4
102100034296 Natriuretic peptides A Human genes 0.000 description 4
101710187800 Natriuretic peptides A Proteins 0.000 description 4
208000002151 Pleural effusion Diseases 0.000 description 4
206010035664 Pneumonia Diseases 0.000 description 4
239000004743 Polypropylene Substances 0.000 description 4
206010062237 Renal impairment Diseases 0.000 description 4
208000012871 acute dyspnea Diseases 0.000 description 4
206010001584 alcohol abuse Diseases 0.000 description 4
208000025746 alcohol use disease Diseases 0.000 description 4
230000008901 benefit Effects 0.000 description 4
210000004351 coronary vessel Anatomy 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
239000000539 dimer Substances 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
238000003018 immunoassay Methods 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
229920001155 polypropylene Polymers 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000000758 substrate Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
108010088751 Albumins Proteins 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
206010007559 Cardiac failure congestive Diseases 0.000 description 3
206010014561 Emphysema Diseases 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
108020001621 Natriuretic Peptide Proteins 0.000 description 3
102000004571 Natriuretic peptide Human genes 0.000 description 3
206010030113 Oedema Diseases 0.000 description 3
101100537532 Rattus norvegicus Tnni3 gene Proteins 0.000 description 3
206010040047 Sepsis Diseases 0.000 description 3
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
210000000038 chest Anatomy 0.000 description 3
208000020832 chronic kidney disease Diseases 0.000 description 3
208000022831 chronic renal failure syndrome Diseases 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
238000003748 differential diagnosis Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000009826 distribution Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
208000019622 heart disease Diseases 0.000 description 3
102000055002 human IL1RL1 Human genes 0.000 description 3
230000036039 immunity Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000000692 natriuretic peptide Substances 0.000 description 3
230000000414 obstructive effect Effects 0.000 description 3
208000008494 pericarditis Diseases 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
108010082126 Alanine transaminase Proteins 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
206010006458 Bronchitis chronic Diseases 0.000 description 2
108010074051 C-Reactive Protein Proteins 0.000 description 2
102100032752 C-reactive protein Human genes 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
208000031229 Cardiomyopathies Diseases 0.000 description 2
238000008157 ELISA kit Methods 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
102000019223 Interleukin-1 receptor Human genes 0.000 description 2
108050006617 Interleukin-1 receptor Proteins 0.000 description 2
206010033307 Overweight Diseases 0.000 description 2
101150095505 ST2 gene Proteins 0.000 description 2
238000008050 Total Bilirubin Reagent Methods 0.000 description 2
238000011256 aggressive treatment Methods 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
206010003119 arrhythmia Diseases 0.000 description 2
230000006793 arrhythmia Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
208000007451 chronic bronchitis Diseases 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
239000003446 ligand Substances 0.000 description 2
238000007477 logistic regression Methods 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
230000004199 lung function Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000010202 multivariate logistic regression analysis Methods 0.000 description 2
231100000857 poor renal function Toxicity 0.000 description 2
208000002815 pulmonary hypertension Diseases 0.000 description 2
238000002601 radiography Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000003118 sandwich ELISA Methods 0.000 description 2
210000000779 thoracic wall Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
208000010444 Acidosis Diseases 0.000 description 1
208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
206010003658 Atrial Fibrillation Diseases 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000029147 Collagen-vascular disease Diseases 0.000 description 1
201000006306 Cor pulmonale Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
206010011906 Death Diseases 0.000 description 1
208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
206010052337 Diastolic dysfunction Diseases 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
208000002251 Dissecting Aneurysm Diseases 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
206010013974 Dyspnoea paroxysmal nocturnal Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
201000000628 Gas Gangrene Diseases 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
241000288140 Gruiformes Species 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
206010051448 Hepatojugular reflux Diseases 0.000 description 1
101000680096 Homo sapiens Transmembrane emp24 domain-containing protein 1 Proteins 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
206010059865 Jugular vein distension Diseases 0.000 description 1
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027417 Metabolic acidosis Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
206010028748 Nasal obstruction Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000027771 Obstructive airways disease Diseases 0.000 description 1
206010030180 Oesophageal pain Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000004327 Paroxysmal Dyspnea Diseases 0.000 description 1
238000010220 Pearson correlation analysis Methods 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
208000032023 Signs and Symptoms Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
206010071436 Systolic dysfunction Diseases 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
206010044003 Tonsillar hypertrophy Diseases 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
102000004987 Troponin T Human genes 0.000 description 1
108090001108 Troponin T Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010046306 Upper respiratory tract infection Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000009798 acute exacerbation Effects 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000007664 blowing Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
208000037998 chronic venous disease Diseases 0.000 description 1
238000010367 cloning Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000002592 echocardiography Methods 0.000 description 1
238000002565 electrocardiography Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000208 fibrin degradation product Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
230000004217 heart function Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
208000000122 hyperventilation Diseases 0.000 description 1
230000000870 hyperventilation Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000009533 lab test Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002171 loop diuretic Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028320 muscle necrosis Diseases 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
210000000107 myocyte Anatomy 0.000 description 1
208000018360 neuromuscular disease Diseases 0.000 description 1
150000007523 nucleic acids Chemical group 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000000053 physical method Methods 0.000 description 1
206010035653 pneumoconiosis Diseases 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
206010037833 rales Diseases 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000012502 risk assessment Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
229960002256 spironolactone Drugs 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
230000008733 trauma Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
210000000264 venule Anatomy 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
General Health & Medical Sciences (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Pathology (AREA)
Medicinal Chemistry (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Rehabilitation Therapy (AREA)
Rheumatology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Saccharide Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Magnetic Resonance Imaging Apparatus (AREA)
Mechanical Treatment Of Semiconductor (AREA)
Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
General Preparation And Processing Of Foods (AREA)

ES10171764T 2006-04-24 2007-04-24 Predicción de la mortalidad y detección de enfermedades graves. Active ES2378314T3 (es)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US79435406P	2006-04-24	2006-04-24
US794354P		2006-04-24
US80036206P	2006-05-15	2006-05-15
US800362P		2006-05-15
US90460807P	2007-03-02	2007-03-02
US904608P		2007-03-02

Publications (1)

Publication Number	Publication Date
ES2378314T3 true ES2378314T3 (es)	2012-04-11

Family

ID=38656334

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
ES10171764T Active ES2378314T3 (es)	2006-04-24	2007-04-24	Predicción de la mortalidad y detección de enfermedades graves.
ES07761219T Active ES2351623T3 (es)	2006-04-24	2007-04-24	Predicción de la mortalidad y detección de una enfermedad grave.
ES11177461.8T Active ES2529618T3 (es)	2006-04-24	2007-04-24	Predicción de la mortalidad y detección de enfermedades graves
ES14188319.9T Active ES2646142T3 (es)	2006-04-24	2007-04-24	Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
ES07761219T Active ES2351623T3 (es)	2006-04-24	2007-04-24	Predicción de la mortalidad y detección de una enfermedad grave.
ES11177461.8T Active ES2529618T3 (es)	2006-04-24	2007-04-24	Predicción de la mortalidad y detección de enfermedades graves
ES14188319.9T Active ES2646142T3 (es)	2006-04-24	2007-04-24	Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2

Country Status (12)

Country	Link
US (7)	US7998683B2 (fr)
EP (5)	EP2386860B1 (fr)
JP (4)	JP5383480B2 (fr)
AT (2)	ATE476657T1 (fr)
AU (1)	AU2007244927B2 (fr)
CA (1)	CA2650201C (fr)
DE (1)	DE602007008224D1 (fr)
DK (3)	DK2848938T3 (fr)
ES (4)	ES2378314T3 (fr)
HK (1)	HK1248311B (fr)
PL (2)	PL2386860T4 (fr)
WO (1)	WO2007127749A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002218026A1 (en)	2000-11-09	2002-05-21	The Brigham And Women's Hospital, Inc.	Cardiovascular disease diagnostic and therapeutic targets
DK3072978T3 (en)	2002-05-09	2018-09-17	Brigham & Womens Hospital Inc	: 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
EP1731910A1 (fr) *	2005-06-07	2006-12-13	F. Hoffmann-La Roche Ag	Utilisation de NT-proANP et NT-proBNP pour le diagnostic de maladies cardiaques
DK2848938T3 (da)	2006-04-24	2017-11-13	Critical Care Diagnostics Inc	Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
EP2021799B1 (fr) *	2006-04-27	2011-07-20	Critical Care Diagnostics, Inc.	Interleukine-33 (il-33) utilisée pour le diagnostic et le pronostic des maladies cardiovasculaires
PT2021796E (pt)	2006-05-01	2012-04-19	Critical Care Diagnostics Inc	Diagnóstico de doença cardiovascular
ES2723957T3 (es) *	2006-05-02	2019-09-04	Critical Care Diagnostics Inc	Procedimiento de selección de un tratamiento basado en el diagnóstico diferencial entre enfermedad pulmonar y cardiovascular
EP2447285A3 (fr) *	2006-05-25	2013-01-16	Momenta Pharmaceuticals, Inc.	Composition d'héparine à faible poids moléculaire et utilisations associées
US12324657B2 (en)	2007-11-28	2025-06-10	Intervet Inc.	System and method for diagnosis of bovine diseases using auscultation analysis
US11389080B2 (en)	2007-11-28	2022-07-19	Intervet Inc.	System and method for diagnosis of bovine diseases using auscultation analysis
WO2009100907A1 (fr) *	2008-02-14	2009-08-20	Dianeering Diagnostics Engineering And Research Gmbh	Moyens et procédés pour évaluer le risque de patients se présentant à des départements d'urgence sur la base de très faibles concentrations de troponine i ou t ou à l'aide d'une combinaison de marqueurs
US20110076729A1 (en) *	2008-02-20	2011-03-31	Momenta Pharmaceuticals, Inc.	Methods of making low molecular weight heparin compositions
JP5526122B2 (ja)	2008-04-18	2014-06-18	クリティカルケアダイアグノスティクスインコーポレイテッド	主要有害心イベントのリスクを予測する方法
EP2141499A1 (fr)	2008-07-02	2010-01-06	Apoptec AG	Diagnostic de MPOC
US9883799B2 (en) *	2008-10-16	2018-02-06	Fresenius Medical Care Holdings, Inc.	Method of identifying when a patient undergoing hemodialysis is at increased risk of death
US20100099958A1 (en) *	2008-10-16	2010-04-22	Fresenius Medical Care Holdings Inc.	Method of identifying when a patient undergoing hemodialysis is at increased risk of death
US10064580B2 (en)	2008-11-07	2018-09-04	Intervet Inc.	System and method for determining antibiotic effectiveness in respiratory diseased animals using auscultation analysis
JP2012063139A (ja) *	2008-12-15	2012-03-29	Hokkaido Univ	糖鎖分析による膵臓がんの診断方法
JP2012063140A (ja) *	2008-12-15	2012-03-29	Hokkaido Univ	糖鎖分析による肺がんの診断方法
US20120322760A1 (en) *	2009-09-23	2012-12-20	Momenta Pharmaceuticals, Inc.	Methods of treatment with a low molecular weight heparin composition
CA2780301A1 (fr) *	2009-11-13	2011-05-19	Bg Medicine, Inc.	Facteurs de risque et prevision d'un infarctus du myocarde
JP6092092B2 (ja) *	2010-03-26	2017-03-08	マイカーティスエヌ．ヴェ．ＭｙＣａｒｔｉｓＮＶ	腎機能障害、糸球体濾過速度、呼吸困難、急性心不全、左心室肥大、心線維症、子癇前症、妊娠関連蛋白尿のバイオマーカーとしてのｌｔｂｐ２
CN106620692B (zh)	2010-04-09	2021-04-09	重症监护诊断股份有限公司	可溶性人st-2抗体和分析法
JP2011232164A (ja) *	2010-04-27	2011-11-17	Keio Gijuku	肝臓疾患マーカー、その測定方法、装置及び医薬品の検定方法
US20110295613A1 (en) *	2010-05-28	2011-12-01	Martin Coyne	Inpatient utilization management system and method
EP2635904A1 (fr) *	2010-11-01	2013-09-11	B.R.A.H.M.S GmbH	Évaluation du pronostic et du risque chez des patients se plaignant de manière non spécifique
GB201021289D0 (en) *	2010-12-15	2011-01-26	Immatics Biotechnologies Gmbh	Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
EP2646823B9 (fr)	2010-12-02	2017-02-22	Fresenius Medical Care Holdings, Inc.	Procédé d'identification d'un risque élevé de mortalité pour un patient en hémodialyse
US8728742B2 (en) *	2011-03-17	2014-05-20	Critical Care Diagnostics, Inc.	Methods predicting risk of an adverse clinical outcome
CA2842072A1 (fr)	2011-07-18	2013-01-24	James V. Snider	Methodes de traitement des maladies cardiovasculaires et de prevision de l'efficacite d'un traitement par l'exercice physique
US20130157290A1 (en) *	2011-12-16	2013-06-20	Yves Levy	Soluble st2 as a marker for disease
EP3434260A1 (fr) *	2012-05-18	2019-01-30	Critical Care Diagnostics, Inc.	Procédés de traitement ou de prédiction du risque d'un événement de tachyarythmie ventriculaire
AR091069A1 (es)	2012-05-18	2014-12-30	Amgen Inc	Proteinas de union a antigeno dirigidas contra el receptor st2
DK2885641T3 (da)	2012-08-16	2018-01-29	Critical Care Diagnostics Inc	Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
JP6450679B2 (ja)	2012-08-21	2019-01-09	クリティカルケアダイアグノスティクスインコーポレイテッド	マルチマーカーリスク層別化
BR112015018929B8 (pt)	2013-02-06	2023-01-31	Geissler Companies Llc	Sistema de saúde eletrônico para determinar a eficácia de uma droga administrada usando análise de auscultação
CA2935958A1 (fr)	2014-01-10	2015-07-16	Critical Care Diagnostics, Inc.	Procedes et systemes de determination du risque d'insuffisance cardiaque
WO2016048388A1 (fr)	2014-09-26	2016-03-31	Somalogic, Inc.	Prédiction d'évènement de risque cardio-vasculaire et leurs utilisations
CN107110871B (zh)	2014-10-29	2019-09-27	豪夫迈·罗氏有限公司	用于死亡的风险预测的生物标志物
JP7231326B2 (ja)	2014-11-10	2023-03-01	ジェネンテック，インコーポレイテッド	Ｉｌ－３３媒介性障害のための治療及び診断方法
CR20170240A (es)	2014-11-10	2018-04-03	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos
US10324089B2 (en)	2014-12-11	2019-06-18	Critical Care Diagnostics, Inc.	Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en)	2014-12-11	2018-09-18	Critical Care Diagnostics, Inc.	Test apparatus and methods for ST2 cardiac biomarker
CN106952043B (zh) *	2017-03-23	2021-04-13	国家电网公司客户服务中心	一种计划停电敏感度评估方法和装置
CN108982871B (zh) *	2018-07-19	2021-09-24	北京市心肺血管疾病研究所	血清sST2在小儿扩张型心肌病预后中的应用
PE20230252A1 (es)	2020-03-13	2023-02-07	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos de estos
US20250259750A1 (en) *	2022-04-15	2025-08-14	Memorial Sloan-Kettering Cancer Center	Multi-modal machine learning to determine risk stratification
WO2025173327A1 (fr) *	2024-02-14	2025-08-21	Ｎｅｃソリューションイノベータ株式会社	Modèle de prédiction de risque d'apparition de maladie et de décès, procédé de prédiction de risque d'apparition de maladie et de décès, dispositif de prédiction de risque d'apparition de maladie et de décès, programme et support d'enregistrement

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4208479A (en) *	1977-07-14	1980-06-17	Syva Company	Label modified immunoassays
US5206140A (en) *	1988-06-24	1993-04-27	Research Corporation Technologies, Inc.	Assay for soluble crosslinked fibrin polymers
JPH0731479Y2 (ja)	1989-06-02	1995-07-19	内橋エステック株式会社	温度ヒューズ
US5217899A (en)	1990-08-24	1993-06-08	The General Hospital Corporation	Cell stretching apparatus
JP2665850B2 (ja)	1991-11-14	1997-10-22	塩野義製薬株式会社	ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en)	1992-06-03	1992-07-15	Medisinsk Innovation A S	Chemical compounds
JPH0731479A (ja)	1993-02-23	1995-02-03	Shinichi Tominaga	マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en)	1995-03-03	2000-05-23	Millennium Pharmaceuticals, Inc.	Methods for the treatment of immune disorders
EP0963205A4 (fr)	1996-08-23	2002-10-02	Human Genome Sciences Inc	Ligand ii du type recepteur de t1
AU6181498A (en)	1997-02-28	1998-09-18	Human Genome Sciences, Inc.	T1/st2-receptor ligand iii
DE19711932A1 (de)	1997-03-21	1998-09-24	Anne Katrin Dr Werenskiold	In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
ES2239801T3 (es)	1997-04-02	2005-10-01	The Brigham And Women's Hospital, Inc.	Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
JP5264026B2 (ja)	1997-06-10	2013-08-14	エルパス・インコーポレイテッド	心疾患の早期発見のための方法
ES2256952T3 (es)	1997-09-11	2006-07-16	SHIONOGI & CO., LTD.	Inmunoanalisis para bnp.
GB9727172D0 (en)	1997-12-24	1998-02-25	Univ Glasgow	Reagents specific for st2l and uses therefor
GB9827348D0 (en)	1998-12-12	1999-02-03	Univ Leicester	Natriuretic peptide
EP1140137A2 (fr)	1998-12-18	2001-10-10	Scios Inc.	Methodes de detection et d'utilisation de genes exprimes de fa on differentielle dans des maladies
AU5309600A (en)	1999-06-02	2000-12-18	Millennium Pharmaceuticals, Inc.	Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr)	1999-07-01	2001-11-23	Inst Nat Sante Rech Med	Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
US6677356B1 (en)	1999-08-24	2004-01-13	Medicure International Inc.	Treatment of cardiovascular and related pathologies
US6323334B1 (en)	1999-09-24	2001-11-27	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) *	2000-03-21	2001-10-03	Takao Arai	Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
FR2807170B1 (fr)	2000-03-30	2002-06-28	Sipal	Charniere elastique a frottement reduit
RU2002110275A (ru)	2000-08-22	2004-03-27	Дзе Брихэм Энд Уимен'З Хоспитал, Инк. (Us)	Диагностика и лечение сердечно-сосудистых состояний
AU2002218026A1 (en)	2000-11-09	2002-05-21	The Brigham And Women's Hospital, Inc.	Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en)	2000-12-07	2003-03-25	Koninklijke Philips Electronics, N.V.	Strain rate analysis in ultrasonic diagnostic images
US7713705B2 (en) *	2002-12-24	2010-05-11	Biosite, Inc.	Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en)	2001-04-13	2004-12-16	Biosite Incorporated	Markers for differential diagnosis and methods of use thereof
EP1322957B1 (fr)	2001-05-04	2009-08-12	Biosite Incorporated	Marqueurs diagnostiques de syndromes coronaires aigus et leurs methodes d'utilisation
US6905827B2 (en)	2001-06-08	2005-06-14	Expression Diagnostics, Inc.	Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (fr)	2001-07-26	2003-03-20	Eos Biotechnology, Inc.	Procedes de diagnostic de l'infection par l'hepatite c, compositions et procedes de criblage de modulateurs de l'infection par l'hepatite c
US6810284B1 (en)	2001-11-21	2004-10-26	Pacesetter, Inc.	Implantable cardiac stimulation system and method for monitoring diastolic function
DK3072978T3 (en)	2002-05-09	2018-09-17	Brigham & Womens Hospital Inc	: 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
MXPA03004105A (es) *	2002-05-14	2004-10-15	Hoffmann La Roche	Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
AU2003239544A1 (en) *	2002-05-24	2003-12-12	Tularik Inc.	Amplification and overexpression of oncogenes
US8263325B2 (en) *	2002-11-15	2012-09-11	Ottawa Heart Institute Research Corporation	Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
US20070042978A1 (en)	2002-12-19	2007-02-22	Jean-Philippe Girard	Nf-hev compositions and methods of use
US20040133079A1 (en) *	2003-01-02	2004-07-08	Mazar Scott Thomas	System and method for predicting patient health within a patient management system
US20040220155A1 (en)	2003-03-28	2004-11-04	Pharmacia Corporation	Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20060257558A1 (en)	2003-10-31	2006-11-16	Hiroshi Nomura	Plasma polymerization of atomically modified surfaces
WO2005056837A2 (fr)	2003-11-26	2005-06-23	Applera Corporation	Polymorphismes genetiques associes a des troubles cardiovasculaires et a une reponse au medicament, leurs procedes de detection et d'utilisation
ES2381551T3 (es)	2003-12-05	2012-05-29	The Cleveland Clinic Foundation	Marcadores de riesgo para enfermedad cardiovascular
US20050196817A1 (en) *	2004-01-20	2005-09-08	Molecular Staging Inc.	Biomarkers for sepsis
NZ549040A (en)	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) *	2004-03-31	2005-10-20	Akira Matsumori	心疾患の検査法
WO2006066095A1 (fr)	2004-12-17	2006-06-22	Clearwater Systems Corporation	Procede et appareil de traitement de fluides
DK1849009T3 (da)	2005-01-24	2009-01-12	Hoffann La Roche Ag F	Anvendelse af cardiachormoner til diagnose af cardiovaskulære risici som fölge af en administration af antiinflammatoriske lægemidler
EP1731910A1 (fr)	2005-06-07	2006-12-13	F. Hoffmann-La Roche Ag	Utilisation de NT-proANP et NT-proBNP pour le diagnostic de maladies cardiaques
US20070021977A1 (en) *	2005-07-19	2007-01-25	Witt Biomedical Corporation	Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (ja)	2006-03-17	2011-11-24	一般財団法人化学及血清療法研究所	急性冠症候群でのａｄａｍｔｓ１３の測定と利用
DK2848938T3 (da)	2006-04-24	2017-11-13	Critical Care Diagnostics Inc	Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
EP2021799B1 (fr)	2006-04-27	2011-07-20	Critical Care Diagnostics, Inc.	Interleukine-33 (il-33) utilisée pour le diagnostic et le pronostic des maladies cardiovasculaires
PT2021796E (pt)	2006-05-01	2012-04-19	Critical Care Diagnostics Inc	Diagnóstico de doença cardiovascular
ES2723957T3 (es)	2006-05-02	2019-09-04	Critical Care Diagnostics Inc	Procedimiento de selección de un tratamiento basado en el diagnóstico diferencial entre enfermedad pulmonar y cardiovascular
US8147817B2 (en)	2006-05-04	2012-04-03	The Brigham And Women's Hospital, Inc.	IL-33 in the treatment and diagnosis of diseases and disorders
RU2312591C1 (ru)	2006-06-14	2007-12-20	Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию"	Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
WO2008116083A1 (fr)	2007-03-22	2008-09-25	Cv Therapeutics, Inc.	Utilisation de ranolazine contre un taux élevé de peptide natriurétique de type b
EP2158330A2 (fr)	2007-05-11	2010-03-03	Tufts Medical Center	Polynucléotides associés à une dégénérescence maculaire liée à l'âge et procédés d'évaluation d'un risque de patient
GB0713404D0 (en)	2007-07-11	2007-08-22	Integra Sp Ipr Ltd	Altio graph
US20100267062A1 (en)	2007-09-26	2010-10-21	Norbert Frey	Osteopontin as Novel Prognostic Biomarker for Heart Failure
FR2923029B1 (fr)	2007-10-26	2009-11-20	Minima	Lunettes de type sans entourage a branches filaires
JP5526122B2 (ja)	2008-04-18	2014-06-18	クリティカルケアダイアグノスティクスインコーポレイテッド	主要有害心イベントのリスクを予測する方法
WO2010054810A1 (fr)	2008-11-11	2010-05-20	B.R.A.H.M.S Ag	Pronostic et évaluation du risque chez des patients souffrant d’insuffisance cardiaque par détermination du taux d’adm et de bnp
CA2780301A1 (fr)	2009-11-13	2011-05-19	Bg Medicine, Inc.	Facteurs de risque et prevision d'un infarctus du myocarde
CN106620692B (zh)	2010-04-09	2021-04-09	重症监护诊断股份有限公司	可溶性人st-2抗体和分析法
EP2635904A1 (fr)	2010-11-01	2013-09-11	B.R.A.H.M.S GmbH	Évaluation du pronostic et du risque chez des patients se plaignant de manière non spécifique
RU2452394C1 (ru)	2010-11-09	2012-06-10	Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет	Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
US8728742B2 (en)	2011-03-17	2014-05-20	Critical Care Diagnostics, Inc.	Methods predicting risk of an adverse clinical outcome
CA2842072A1 (fr)	2011-07-18	2013-01-24	James V. Snider	Methodes de traitement des maladies cardiovasculaires et de prevision de l'efficacite d'un traitement par l'exercice physique
EP3434260A1 (fr)	2012-05-18	2019-01-30	Critical Care Diagnostics, Inc.	Procédés de traitement ou de prédiction du risque d'un événement de tachyarythmie ventriculaire
DK2885641T3 (da)	2012-08-16	2018-01-29	Critical Care Diagnostics Inc	Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
JP6450679B2 (ja)	2012-08-21	2019-01-09	クリティカルケアダイアグノスティクスインコーポレイテッド	マルチマーカーリスク層別化
JP6178687B2 (ja)	2013-09-27	2017-08-09	富士機械工業株式会社	グラビア塗工装置
CA2935958A1 (fr)	2014-01-10	2015-07-16	Critical Care Diagnostics, Inc.	Procedes et systemes de determination du risque d'insuffisance cardiaque
USD770057S1 (en)	2014-04-14	2016-10-25	Critical Care Diagnostics, Inc.	Blood test kit
US9934249B2 (en)	2014-06-03	2018-04-03	Conduent Business Machines Services, Llc	Systems and methods for context-aware and personalized access to visualizations of road events
USD800332S1 (en)	2014-09-23	2017-10-17	Critical Care Diagnostics, Inc.	Blood test kit
USD800333S1 (en)	2014-09-23	2017-10-17	Critical Care Diagnostics, Inc.	Blood test kit
US10324089B2 (en)	2014-12-11	2019-06-18	Critical Care Diagnostics, Inc.	Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en)	2014-12-11	2018-09-18	Critical Care Diagnostics, Inc.	Test apparatus and methods for ST2 cardiac biomarker

2007
- 2007-04-24 DK DK14188319.9T patent/DK2848938T3/da active
- 2007-04-24 ES ES10171764T patent/ES2378314T3/es active Active
- 2007-04-24 ES ES07761219T patent/ES2351623T3/es active Active
- 2007-04-24 US US11/789,169 patent/US7998683B2/en active Active
- 2007-04-24 AU AU2007244927A patent/AU2007244927B2/en not_active Ceased
- 2007-04-24 WO PCT/US2007/067333 patent/WO2007127749A2/fr not_active Ceased
- 2007-04-24 ES ES11177461.8T patent/ES2529618T3/es active Active
- 2007-04-24 DE DE602007008224T patent/DE602007008224D1/de active Active
- 2007-04-24 EP EP11177461.8A patent/EP2386860B1/fr not_active Not-in-force
- 2007-04-24 PL PL11177461T patent/PL2386860T4/pl unknown
- 2007-04-24 DK DK11177461.8T patent/DK2386860T3/en active
- 2007-04-24 AT AT07761219T patent/ATE476657T1/de active
- 2007-04-24 ES ES14188319.9T patent/ES2646142T3/es active Active
- 2007-04-24 EP EP07761219A patent/EP2010912B1/fr not_active Not-in-force
- 2007-04-24 AT AT10171764T patent/ATE527544T1/de active
- 2007-04-24 CA CA2650201A patent/CA2650201C/fr not_active Expired - Fee Related
- 2007-04-24 EP EP17177530.7A patent/EP3255432B1/fr not_active Not-in-force
- 2007-04-24 DK DK10171764.3T patent/DK2241888T3/da active
- 2007-04-24 EP EP14188319.9A patent/EP2848938B1/fr not_active Not-in-force
- 2007-04-24 EP EP10171764A patent/EP2241888B1/fr not_active Not-in-force
- 2007-04-24 JP JP2009507931A patent/JP5383480B2/ja not_active Expired - Fee Related
- 2007-04-24 PL PL14188319T patent/PL2848938T3/pl unknown
2011
- 2011-07-08 US US13/179,173 patent/US8617825B2/en not_active Expired - Fee Related
- 2011-10-26 US US13/282,111 patent/US9568481B2/en active Active - Reinstated
2012
- 2012-04-26 JP JP2012100940A patent/JP5806165B2/ja not_active Expired - Fee Related
2013
- 2013-03-07 US US13/787,975 patent/US9057733B2/en not_active Expired - Fee Related
2015
- 2015-09-03 JP JP2015173815A patent/JP6214604B2/ja not_active Expired - Fee Related
- 2015-09-17 HK HK18107615.0A patent/HK1248311B/en not_active IP Right Cessation
2017
- 2017-01-19 US US15/410,155 patent/US10067146B2/en active Active
- 2017-09-19 JP JP2017178945A patent/JP2017215347A/ja active Pending
2018
- 2018-08-13 US US16/101,939 patent/US11016103B2/en not_active Expired - Fee Related
2021
- 2021-04-27 US US17/241,303 patent/US20210255200A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20140045200A1 (en)	2014-02-13
US20170131294A1 (en)	2017-05-11
EP2241888B1 (fr)	2011-10-05
US20120040381A1 (en)	2012-02-16
DK2848938T3 (da)	2017-11-13
JP5383480B2 (ja)	2014-01-08
EP2386860A3 (fr)	2012-02-22
CA2650201A1 (fr)	2007-11-08
EP3255432A1 (fr)	2017-12-13
JP5806165B2 (ja)	2015-11-10
US9568481B2 (en)	2017-02-14
EP2241888A3 (fr)	2010-11-03
HK1208724A1 (en)	2016-03-11
US8617825B2 (en)	2013-12-31
EP2386860B1 (fr)	2014-11-05
US10067146B2 (en)	2018-09-04
JP2016001193A (ja)	2016-01-07
CA2650201C (fr)	2020-10-20
DE602007008224D1 (de)	2010-09-16
WO2007127749A3 (fr)	2008-03-20
PL2386860T3 (pl)	2015-08-31
US20070248981A1 (en)	2007-10-25
HK1248311B (en)	2020-03-20
ES2351623T3 (es)	2011-02-08
EP2848938A1 (fr)	2015-03-18
ATE476657T1 (de)	2010-08-15
EP2010912B1 (fr)	2010-08-04
EP2241888A2 (fr)	2010-10-20
JP2017215347A (ja)	2017-12-07
EP2848938B1 (fr)	2017-08-02
US9057733B2 (en)	2015-06-16
ES2529618T3 (es)	2015-02-23
PL2386860T4 (pl)	2015-09-30
US7998683B2 (en)	2011-08-16
WO2007127749A2 (fr)	2007-11-08
AU2007244927A1 (en)	2007-11-08
EP3255432B1 (fr)	2019-01-23
US20210255200A1 (en)	2021-08-19
ES2646142T3 (es)	2017-12-12
HK1164443A1 (en)	2012-09-21
EP2010912A2 (fr)	2009-01-07
US20110262941A1 (en)	2011-10-27
US20190041403A1 (en)	2019-02-07
JP2012181200A (ja)	2012-09-20
ATE527544T1 (de)	2011-10-15
DK2241888T3 (da)	2012-01-30
PL2848938T3 (pl)	2018-02-28
DK2386860T3 (en)	2015-02-09
JP6214604B2 (ja)	2017-10-18
EP2010912A4 (fr)	2009-06-10
EP2386860A2 (fr)	2011-11-16
JP2009534691A (ja)	2009-09-24
AU2007244927B2 (en)	2012-01-12
US11016103B2 (en)	2021-05-25

Publication	Publication Date	Title
ES2378314T3 (es)	2012-04-11	Predicción de la mortalidad y detección de enfermedades graves.
DK2660599T3 (en)	2014-12-08	PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS
HK1248311A1 (en)	2018-10-12	Predicting mortality and detecting severe disease
AU2016200419B2 (en)	2018-01-25	Predicting mortality and detecting severe disease
AU2012202069B2 (en)	2015-11-05	Predicting mortality and detecting severe disease
HK1208724B (en)	2018-06-29	Evaluating the efficacy of a treatment in a subject based on st2 levels
HK1164443B (en)	2015-09-25	Predicting mortality and detecting severe disease